‹ News Blitz Science & Technology Developing

India’s HPV vaccination campaign crosses 80 lakh doses

English हिंदी ಕನ್ನಡ മലയാളം தமிழ் తెలుగు

First brief 11 Sep, 3:47 pm IST Updated 11 Sep, 3:47 pm IST 1 development 2 min read Latest ↓

File photo: Gardasil packaging in Japan, 2016 — melvil · CC BY-SA 4.0

Where it stands

India’s free human papillomavirus (HPV) vaccination campaign has delivered more than 80 lakh doses, the Health Ministry announced on 11 September 2026. The programme offers a single dose to girls aged fourteen, with parental consent. Vaccination helps prevent infection by virus types responsible for many cervical cancers. The campaign began on 28 February and continues through government health facilities, including routine immunisation days. Girls already vaccinated against HPV are recorded on U-WIN rather than automatically vaccinated again under the campaign. The milestone measures vaccine delivery, not cancers already prevented or complete national coverage. Vaccination also does not remove the later need for cervical screening.

Background

Cervical cancer affects the cervix, the lower part of the womb. Persistent infection with certain types of human papillomavirus, or HPV, can gradually cause abnormal cells to develop there. Most HPV infections clear, but some continue and can eventually lead to cancer. Vaccination works best before exposure to the virus, which explains the focus on adolescents. India’s programme turns prevention into a free public service for a defined age group. Reaching girls who have missed vaccination remains important, while screening and treatment address risks that vaccination alone cannot remove.

How it developed

28 February 2026: national campaign launched

How it started
The national programme made vaccination free for fourteen-year-old girls

The national campaign began in Ajmer on 28 February 2026. Government facilities offered one dose of the quadrivalent Gardasil vaccine to eligible girls, with parental or guardian consent. Quadrivalent means the vaccine targets four HPV types. Eligibility covered girls who had completed fourteen years but had not turned fifteen. Registration was available through U-WIN, with walk-in registration also allowed. After the initial ninety-day campaign, vaccination was to continue on routine immunisation days. Previously vaccinated girls were excluded from repeat campaign vaccination, with their status recorded instead. The service is voluntary, not a compulsory vaccination order.

Health Ministry / PIB PIB World Health Organization
11 September 2026: more than 80 lakh doses reported

New fact
The next task is to reach eligible girls still left out

The Health Ministry reported more than 80 lakh doses on 11 September 2026. U-WIN records help officials identify districts and eligible groups where coverage remains incomplete. The ministry said some States had vaccinated their entire identified target cohorts; that does not mean every Indian girl has been vaccinated. The programme remains free and voluntary for eligible girls. Trained medical officers supervise sessions, with facilities linked for managing adverse events after immunisation. Continued delivery matters because a cumulative milestone alone does not show whether access is even across places. The announcement does not measure a fall in cancer cases.

Health Ministry / PIB World Health Organization PTI / Business Standard

Why it matters for UPSC

GS2 · Public healthGS3 · Vaccine science

For GS2 and GS3, connect preventive health, public-service delivery and vaccine science. Separate doses delivered from disease outcomes and from the share of an eligible population reached. Vaccination, screening and treatment perform different jobs in cervical-cancer prevention and care.

Key terms

Human papillomavirus or HPVA group of viruses, some of which can cause cancers. HPV infection is common and is usually passed through sexual contact. Most infections clear naturally; persistent infection with high-risk types can cause harmful cell changes. Having an HPV infection does not mean that a person already has cancer.

Cervix and cervical cancerThe cervix is the lower part of the womb, opening into the vagina. Cervical cancer develops when abnormal cells there grow uncontrollably. Preventing high-risk HPV infection can lower future risk. Vaccination is prevention, not treatment for an existing cancer or a way to diagnose one.

Quadrivalent vaccineA vaccine targeting four types of the same virus group. The campaign uses Gardasil against HPV types 6, 11, 16 and 18. The types do not all have the same health effects. Quadrivalent describes the vaccine’s coverage, not four injections: the Indian campaign provides a single dose.

Eligible cohort and coverageA cohort is a defined group, such as girls in the programme’s specified age range. Coverage measures how much of that group has been reached. A State reporting full coverage of its identified cohort is not saying that all girls of every age have been vaccinated. The denominator matters.

U-WINThe government’s digital system for recording and managing vaccination services. The campaign uses these records to track delivery and identify coverage gaps. An existing HPV vaccination can be recorded rather than treated as a reason to repeat the campaign dose. Registration is an administrative step, not proof that vaccination has happened.

Routine immunisation daysRegular vaccination sessions at public health facilities, distinct from the initial concentrated campaign. The HPV programme was designed to continue through these sessions after the first ninety days. Ending that intensive phase therefore did not mean that the free service had been withdrawn from eligible girls.

ScreeningChecking for infection or early cell changes before symptoms appear. Screening can identify people who need further assessment or treatment. Vaccination reduces future risk but does not replace screening later in life. Screening, diagnosis and treatment are related stages, not interchangeable names for the same procedure.

Adverse event following immunisationA health problem occurring after vaccination that requires assessment. The timing alone does not establish that the vaccine caused it. The programme links vaccination sites with facilities equipped to respond. Monitoring such events is part of safe service delivery, not a claim that every reported problem has the same cause.

Sources (6)

Health Ministry / PIB · official · National HPV vaccination launch and eligibility, 28 February 2026
PIB · official · HPV programme background, prior vaccination and routine continuation
World Health Organization · official · Cervical cancer: infection, prevention and screening
Health Ministry / PIB · official · National HPV vaccination campaign crosses 80 lakh doses, 11 September 2026
World Health Organization · official · Adverse events after immunisation: timing and causality differ
PTI / Business Standard · India crosses 80 lakh HPV vaccinations under the nationwide campaign